# CABOLIFE: A Prospective Non-Interventional Study on Effectiveness and Safety of Cabozantinib in Real-Life Setting for Previously Treated Patients with Neuroendocrine Tumours

First published: 30/10/2025
Last updated: 30/10/2025





# Administrative details

EU PAS number
EUPAS1000000752
Study ID
100000752
DARWIN EU® study
No
Study countries
Austria
Germany

## Study description

This study will assess how well cabozantinib works and how safe it is in adults with a type of cancer called neuroendocrine tumors (NETs).

These tumors can appear in all parts of the body. All participants in this study have already received at least one treatment that affects the whole body to help manage their cancer, but their disease has continued to grow.

The study will take place in regular hospitals and clinics in Germany and Austria.

It will follow about 150 participants who are taking cabozantinib as part of their usual care. Doctors will collect information from routine medical visits, tests, and scans to see how the cancer responds to treatment and how long participants stay on cabozantinib. They will also look at side effects and how the treatment affects participants' quality of life.

This is an observational study, which means that no extra tests or procedures will be done beyond what is normally used to care for participants with this condition.

## **Study status**

Planned

# Contact details

# Study institution contact

Ipsen Clinical Study Enquiries clinical.trials@ipsen.com

Study contact

clinical.trials@ipsen.com

## **Primary lead investigator**

Ipsen Medical Director

# Study timelines

## Date when funding contract was signed

Planned: 13/08/2025

Actual: 13/08/2025

#### Study start date

Planned: 27/10/2025

## **Date of final study report**

Planned: 31/12/2029

# Sources of funding

• Pharmaceutical company and other private sector

# Study protocol

clin60000467 16.1.1 protocol V1.0 2025Jul30 Redacted.pdf (7.85 MB)

# Regulatory

## Was the study required by a regulatory body?

Unknown

## Is the study required by a Risk Management Plan (RMP)?

Not applicable

# Methodological aspects

#### Study type:

Non-interventional study

## Scope of the study:

Effectiveness study (incl. comparative)

Safety study (incl. comparative)

#### **Data collection methods:**

Primary data collection

#### Study design:

Prospective, multicentre, non-interventional, single-arm study conducted in Germany and Austria with 150 adult participants with pNET or epNET.

Observational period: up to 18 months wich includes 3-month follow-up if treatment discontinued.

## Main study objective:

To describe the effectiveness of cabozantinib tablets in participantswith previously treated neuroendocrine tumours (NETs) in real-life in terms of disease control rate (DCR) at 6 months of cabozantinib treatment as assessed by the treating physician.

# Study Design

## Non-interventional study design

Cohort

# Study drug and medical condition

#### Name of medicine

CABOMETYX

## Study drug International non-proprietary name (INN) or common name

**CABOZANTINIB** 

#### Medical condition to be studied

Pancreatic neuroendocrine tumour metastatic

#### Additional medical condition(s)

Unresectable or metastatic, well-differentiated pancreatic and extra-pancreatic neuroendocrine tumours (pNET/epNET) after prior systemic therapy

# Population studied

## Short description of the study population

150 adult participants in Austria and Germany who are prescribed cabozantinib tablets for unresectable or metastatic, well differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumours who have progressed following at least one prior systemic therapy other than somatostatin analogues prior to entry into the study will be included.

#### Age groups

Adult and elderly population (≥18 years)

Adults (18 to < 65 years)

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Elderly (≥ 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

# Study design details

#### **Outcomes**

Primary Outcome Measure:

- Disease Control Rate (DCR) at 6 Months Secondary Outcome Measure:
- Objective Response Rate (ORR) up to 18 Months
- Change from baseline in global and subscale scores of the European
   Organisation for Research and Treatment of Cancer Quality of Life
   Questionnaire Core 30 (EORTC QLQ-C30), at baseline and Every 3 Months up to 18 Months.
- Change from baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Gastrointestinal Neuroendocrine Tumors Module (EORTC QLQ-GINET21), baseline and Every 3 Months up to 18 Months
- Percentage of participants experiencing Adverse Events (AEs), non-serious, drug-related, or serious Adverse Events (SAEs), up to 18 Months
- Frequency of Dose Modifications Due to Adverse Events, up to 18 months
- Duration of treatment (DoT), up to 18 Months
- Proportion of participants switching to a new line of therapy and type of therapy received, up to 18 Months
- Disease Control Rate After Switch to Next Line of Therapy, 3 Months After Therapy Switch
- Chromogranin A Levels, baseline and Every 3 Months up to 18 Months
- Neuron-Specific Enolase blood levels, baseline and Every 3 Months up to 18 Months
- Time to next treatment (TTNT), up to 18 Months

- Progression-Free Survival (PFS), up to 18 Months
- Progression-Free Survival Rate at 12 and 18 Months

#### Data analysis plan

In this non-interventional study, all the analyses will be primarily descriptive in nature.

The primary endpoint will be DCR of cabozantinib-treated NET participants; the rate of disease control will be presented with the 95% confidence interval (CI). Secondary endpoints, i.e. ORR, QoL, safety, DCR of subsequent treatment, DoT, as well as TTNT will be presented descriptively. The Kaplan-Meier method will be used to obtain the estimates of median PFS (time between the start of treatment with cabozantinib until progression assessed clinically or via imaging as observed by the treating physician or death from any cause) and their associated two-sided 95% CIs or landmark 12-month and 18-month PFS. Subgroup analyses will be only performed if data permit and subgroups may be merged into larger subgroups if deemed necessary. The subgroups will be based of NET localization (Lung NET, Gastro-Intestinal NET, pNET and other NET).

# Data management

# **ENCePP Seal**

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

## Data sources

## Data sources (types)

Non-interventional study

# Use of a Common Data Model (CDM)

## **CDM** mapping

No

# Data quality specifications

#### **Check conformance**

Unknown

## **Check completeness**

Unknown

## **Check stability**

Unknown

## **Check logical consistency**

Unknown

# Data characterisation

#### **Data characterisation conducted**

No